A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Trial Profile

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms JAVELIN Marker 200; JAVELIN Merkel 200
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 21 Jul 2017 According to a Merck media release, enrolment in Part B of the study is ongoing and is planned to include 112 treatment-naive patients.
    • 21 Jul 2017 According to a Merck media release, based on the data from this trial, European Medicines Agency (EMA) has recommended the approval of avelumab (BAVENCIO) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC).
    • 13 Jul 2017 Planned End Date changed from 31 May 2019 to 30 Jun 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top